Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Research analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.43) for the year, up from their prior forecast of ($0.44). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2027 earnings at ($0.32) EPS.
Separately, Oppenheimer restated an “outperform” rating and issued a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.67.
Corvus Pharmaceuticals Trading Up 0.3 %
Shares of CRVS stock opened at $3.38 on Friday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The firm’s 50 day moving average is $4.61 and its 200-day moving average is $6.06. The firm has a market capitalization of $217.19 million, a price-to-earnings ratio of -3.63 and a beta of 0.91.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06).
Institutional Investors Weigh In On Corvus Pharmaceuticals
Several institutional investors have recently modified their holdings of CRVS. RTW Investments LP bought a new position in Corvus Pharmaceuticals in the fourth quarter valued at approximately $14,335,000. Foresite Capital Management VI LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $8,460,000. Deerfield Management Company L.P. Series C bought a new position in shares of Corvus Pharmaceuticals in the 4th quarter worth $5,350,000. Vivo Capital LLC grew its stake in shares of Corvus Pharmaceuticals by 49.2% during the fourth quarter. Vivo Capital LLC now owns 2,234,566 shares of the company’s stock worth $11,955,000 after purchasing an additional 737,298 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in Corvus Pharmaceuticals in the fourth quarter valued at about $2,678,000. Institutional investors and hedge funds own 46.64% of the company’s stock.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Further Reading
- Five stocks we like better than Corvus Pharmaceuticals
- There Are Different Types of Stock To Invest In
- MarketBeat Week in Review – 03/24 – 03/28
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to buy stock: A step-by-step guide for beginners
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
